At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 24 enrolled
Drug / intervention
Phentolamine Mesylate Ophthalmic Solution 1% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances
In Brief
A Phase 2 clinical trial evaluating Phentolamine Mesylate Ophthalmic Solution 1% and Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo) for Decrease in Night Vision and Disturbance; Vision, Loss. Completed, enrolled 24 participants across 1 site.
Detailed Summary
The objectives of this study are: * To assess the effect of ophthalmic phentolamine mesylate in mesopic conditions on the four endpoints: 1. Contrast sensitivity 2. Low contrast visual acuity 3. Wavefront aberrometry 4. Subjective questionnaire * To assess the safety of ophthalmic phentolamine mesylate
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsOphthalmic Consultants of Long Island
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2007
Primary CompletionOct 2007
Study CompletionFeb 2008
First PostedJul 2019
TodayJul 2026
First PostedJul 2, 2019
Enrollment StartAug 1, 2007
Primary CompletionOct 1, 2007
Study CompletionFeb 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 7 years ago
Interventions
Phentolamine Mesylate Ophthalmic Solution 1%drug
Topical Sterile Ophthalmic Solution
Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)other
Topical Sterile Ophthalmic Solution